HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review
Abstract
:1. Introduction
2. Defining Hepatitis B Reactivation
3. Mechanisms of HBV Reactivation
3.1. HBV
3.2. Immunity
3.3. Immunoppressive Drugs
4. Clinical Outcomes of HBV Reactivation
5. Interplay of Risk Factors for HBV Reactivation in HSCT
5.1. Host Risk Factors
5.2. Virologic Factors for HSCT
5.3. Type and Degree of Immunodepression
6. Management of HBV Reactivation
6.1. Screening
6.2. Prophylaxis of HBV Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic or Past HBV Infection
6.2.1. Prophylaxis of HBV Reactivation in Allo-HSCT Recipients with Chronic HBV Infection
6.2.2. Prophylaxis of HBV Reactivation in Allo-HSCT Recipients with Past HBV Infection
6.2.3. Management of HBV Infection in Allo-HSCT Donor
6.3. Prophylaxis of HBV Reactivation in Autologous Hematopoietic Stem Cell Transplantation Patients with Chronic or Past HBV Infection
6.4. HBV Vaccination
7. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- WHO. Global Hepatitis Report. 2017. Available online: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (accessed on 4 April 2019).
- Martin, P.; Lau, D.T.; Nguyen, M.H.; Janssen, H.L.; Dieterich, D.T.; Peters, M.G.; Jacobson, I.M. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 update. Clin. Gastroenterol. Hepatol. 2015, 13, 2071–2087. [Google Scholar] [CrossRef]
- Hope, V.D.; Eramova, I.; Capurro, D.; Donoghoe, M.C. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: A review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol. Infect. 2014, 142, 270–286. [Google Scholar] [CrossRef]
- WHO. WHO Hepatitis. Available online: http://www.who.int/immunization/topics/hepatitis/en/ (accessed on 24 January 2018).
- Perrillo, R.P.; Gish, R.; Falck-Ytter, Y.T. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015, 148, 221–244. [Google Scholar] [CrossRef] [PubMed]
- Mindikoglu, A.L.; Regev, A.; Schiff, E.R. Hepatitis B virus reactivation after cytotoxic chemotherapy: The disease and its prevention. Clin. Gastroenterol. Hepatol. 2006, 4, 1076–1081. [Google Scholar] [CrossRef] [PubMed]
- Gentile, G.; Andreoni, M.; Antonelli, G.; Sarmati, L. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: A systematic review. Clin. Microbiol. Infect. 2017, 23, 916–923. [Google Scholar] [CrossRef] [PubMed]
- Viganò, M.; Vener, C.; Lampertico, P.; Annaloro, C.; Pichoud, C.; Zoulim, F.; Facchetti, F.; Poli, F.; Scalamogna, M.; Deliliers, G.L.; et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011, 46, 125–131. [Google Scholar] [CrossRef]
- Hammond, S.P.; Borchelt, A.M.; Ukomadu, C.; Ho, V.T.; Baden, L.R.; Marty, F.M. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2009, 15, 1049–1059. [Google Scholar] [CrossRef]
- Nakamoto, S.; Kanda, T.; Nakaseko, C.; Sakaida, E.; Ohwada, C.; Takeuchi, M.; Takeda, Y.; Mimura, N.; Iseki, T.; Wu, S.; et al. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: Efficacy of nucleos(t)ide analogues for prevention and treatment. Int. J. Mol. Sci. 2014, 15, 21455–21467. [Google Scholar] [CrossRef]
- Mikulska, M.; Nicolini, L.; Signori, A.; Rivoli, G.; Del Bono, V.; Raiola, A.M.; Di Grazia, C.; Dominietto, A.; Varaldo, R.; Ghiso, A.; et al. Hepatitis B reactivation in HBsAg-negative/HBcAbpositive allogeneic haematopoietic stem cell transplant recipients: Risk factors and outcome. Clin. Microbiol. Infect. 2014, 20, 694–701. [Google Scholar] [CrossRef]
- Huang, H.; Cai, Q.; Lin, T.; Lin, X.; Liu, Y.; Gao, Y.; Peng, R. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin’s lymphoma single institution experience. Expert Opin. Pharmacother. 2009, 10, 2399–2406. [Google Scholar] [CrossRef]
- Bertoletti, A.; Rivino, L. Hepatitis B: Future curative strategies. Curr. Opin. Infect. Dis. 2014, 27, 528–534. [Google Scholar] [CrossRef] [PubMed]
- Yang, N.; Bertoletti, A. Advances in therapeutics for chronic hepatitis B. Hepatol. Int. 2016, 10, 277–285. [Google Scholar] [CrossRef] [PubMed]
- Salpini, R.; Colagrossi, L.; Bellocchi, M.C.; Surdo, M.; Becker, C.; Alteri, C.; Aragri, M.; Ricciardi, A.; Armenia, D.; Pollicita, M.; et al. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology 2015, 61, 823–833. [Google Scholar] [CrossRef] [PubMed]
- Inuzuka, T.; Ueda, Y.; Arasawa, S.; Takeda, H.; Matsumoto, T.; Osaki, Y.; Uemoto, S.; Seno, H.; Marusawa, H. Expansion of viral variants associated with immune escape and impaired virion secretion in patients with HBV reactivation after resolved infection. Sci. Rep. 2018, 8, 18070. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Inoue, J.; Nakamura, T.; Masamune, A. Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies. Viruses 2019, 11, 457. [Google Scholar] [CrossRef] [PubMed]
- Lazarevic, I.; Banko, A.; Miljanovic, D.; Cupic, M. Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression. Viruses 2019, 11, 778. [Google Scholar] [CrossRef]
- Ljungman, P.; Bregni, M.; Brune, M.; Cornelissen, J.; de Witte, T.; Dini, G.; Einsele, H.; Gaspar, H.B.; Gratwohl, A.; Passweg, J.; et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe 2009. Bone Marrow Transplant. 2010, 45, 219–234. [Google Scholar] [CrossRef]
- Inamoto, Y.; Lee, S.J. Late effects of blood and marrow transplantation. Haematologica 2017, 102, 614–625. [Google Scholar] [CrossRef]
- McDonald, G.B. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010, 51, 1450–1460. [Google Scholar] [CrossRef]
- van den Brink, M.R.M.; Velardi, E.; Perales, M.A. Immune reconstitution following stem cell transplantation. Hematol. Am. Soc. Hematol. Educ. Program. 2015, 2015, 215–219. [Google Scholar] [CrossRef] [Green Version]
- Sarmati, L.; Andreoni, M.; Antonelli, G.; Arcese, W.; Bruno, R.; Coppola, N.; Gaeta, G.B.; Galli, M.; Girmenia, C.; Mikulska, M.; et al. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—A position paper. Clin. Microbiol. Infect. 2017, 23, 935–940. [Google Scholar] [CrossRef] [PubMed]
- Terrault, N.A.; Lok, A.S.F.; McMahon, B.J.; Chang, K.M.; Hwang, J.P.; Jonas, M.M.; Brown, R.S., Jr.; Bzowej, N.H.; Wong, J.B. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018, 67, 1560–1599. [Google Scholar] [CrossRef] [PubMed]
- Visram, A.; Feld, J.J. Defining and grading HBV reactivation. Clin. Liver Dis. 2015, 5, 35–38. [Google Scholar] [CrossRef] [PubMed]
- Seeger, C.; Mason, W.S. Molecular biology of hepatitis B virus infection. Virology 2015, 479–480, 672–686. [Google Scholar] [CrossRef] [PubMed]
- Revill, P.A.; Chisari, F.V.; Block, J.M.; Dandri, M.; Gehring, A.J.; Guo, H.; Hu, J.; Kramvis, A.; Lampertico, P.; A Janssen, H.L.; et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 2019, 4, 545–558. [Google Scholar] [CrossRef]
- Maini, M.K.; Pallett, L.J. Defective T-cell immunity in hepatitis B virus infection: Why therapeutic vaccinations needs helping hand. Lancet Gastroenterol. Hepatol. 2018, 3, 192–202. [Google Scholar] [CrossRef]
- Hu, J.; Protzer, U.; Siddiqui, A. Revisiting Hepatitis B virus: Challenges of Curative Therapies. J. Virol. 2019, 93, e01032-19. [Google Scholar] [CrossRef]
- Yan, H.; Zhong, G.; Xu, G.; He, W.; Jing, Z.; Gao, Z.; Huang, Y.; Qi, Y.; Peng, B.; Wang, H.; et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012, 1, e00049. [Google Scholar] [CrossRef]
- Bock, C.T.; Schwinn, S.; Locarnini, S.; Fyfe, J.; Manns, M.P.; Trautwein, C.; Zentgraf, H. Structural organization of the hepatitis B virus minichromosome. J. Mol. Biol. 2001, 307, 183–196. [Google Scholar] [CrossRef]
- Pollicino, T.; Belloni, L.; Raffa, G.; Pediconi, N.; Squadrito, G.; Raimondo, G.; Levrero, M. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006, 130, 823–837. [Google Scholar] [CrossRef]
- Rehermann, B.; Ferrari, C.; Pasquinelli, C.; Chisari, F.V. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 1996, 2, 1104–1108. [Google Scholar] [CrossRef] [PubMed]
- Werle-Lapostolle, B.; Bowden, S.; Locarnini, S.; Wursthorn, K.; Petersen, J.; Lau, G.; Trepo, C.; Marcellin, P.; Goodman, Z.; Delaney, W.E.; et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126, 1750–1758. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sung, J.J.; Wong, M.-L.; Bowden, S.; Liew, C.-T.; Hui, A.Y.; Wong, V.W.; Leung, N.W.; Locarnini, S.; Chan, H.L. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005, 128, 1890–1897. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.-Y.; Hu, K.-Q. Rethinking the Pathogenesis of Hepatitis B Virus (HBV) Infection. J. Med. Virol. 2015, 87, 1989–1999. [Google Scholar] [CrossRef] [PubMed]
- Chang, M.L.; Liaw, Y.F. Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management. J. Hepatol. 2014, 61, 1407–1417. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Raimondo, G.; Locarnini, S.; Pollicino, T.; Levrero, M.; Zoulim, F.; Lok, A.S.; Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J. Hepatol. 2019, 71, 397–408. [Google Scholar] [CrossRef] [Green Version]
- Yip, T.C.; Wong, G.L. Current Knowledge of Occult Hepatitis B Infection and Clinical Implications. Semin. Liver Dis. 2019, 39, 249–260. [Google Scholar] [CrossRef]
- Anastasiou, O.E.; Almpani, F.; Herrmann, A.; Gerken, G.; Ditschkowski, M.; Ciesek, S. HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations. Hepatol. Commun. 2017, 1, 1014–1023. [Google Scholar] [CrossRef]
- Maini, M.K.; Gehring, A.J. The role of innate immunity in the immunopathology and treatment of HBV infection. J. Hepathol. 2016, 64, S60–S70. [Google Scholar] [CrossRef] [Green Version]
- Bertoletti, A.; Ferrari, C. Adaptive immunity in HBV infection. J. Hepatol. 2016, 64, S71–S83. [Google Scholar] [CrossRef]
- Guidotti, L.G.; Chisari, F.V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 2006, 1, 23–61. [Google Scholar] [CrossRef] [PubMed]
- Tsai, K.N.; Kuo, C.F.; Ou, J.J. Mechanisms of Hepatitis B Virus Persistence. Trends Microbiol. 2018, 26, 33–42. [Google Scholar] [CrossRef] [PubMed]
- Faure-Dupuy, S.; Lucifora, J.; Durantel, D. Interplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts. Viruses 2017, 9, 95. [Google Scholar] [CrossRef] [PubMed]
- Wieland, S.F.; Chisari, F.V. Stealth and cunning: Hepatitis B and hepatitis C viruses. J. Virol. 2005, 79, 9369–9380. [Google Scholar] [CrossRef] [PubMed]
- Mutz, P.; Metz, P.; Lempp, F.A.; Bender, S.; Qu, B.; Schöneweis, K.; Seitz, S.; Tu, T.; Restuccia, A.; Frankish, J.; et al. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. Gastroenterology 2018, 154, 1791–1804. [Google Scholar] [CrossRef] [PubMed]
- Suslov, A.; Boldanova, T.; Wang, X.; Wieland, S.; Heim, M.H. Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver. Gastroenterology 2018, 154, 1778–1790. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lau, G.K.; Lok, A.S.; Liang, R.H.; Lai, C.L.; Chiu, E.K.; Lau, Y.L.; Lam, S.K. Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer. Hepatology 1997, 25, 1497–1501. [Google Scholar] [CrossRef]
- Lau, G.K.; Liang, R.; Lee, C.K.; Yuen, S.T.; Hou, J.; Lim, W.L.; Williams, R. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. J. Infect. Dis. 1998, 178, 1585–1591. [Google Scholar] [CrossRef]
- Ilan, Y.; Nagler, A.; Zeira, E.; Adler, R.; Slavin, S.; Shouval, D. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients. Bone Marrow Transplant. 2000, 26, 633–638. [Google Scholar] [CrossRef] [Green Version]
- Kimura, M.; Nishikawa, K.; Sakamaki, H.; Mizokami, M.; Kimura, K. Reduced therapeutic effect of antiviral drugs in patients with hepatitis B virus reactivation after hematopoietic stem cell transplantation. Hepatol. Res. 2018, 48, 469–478. [Google Scholar] [CrossRef]
- Liu, J.H.; Liao, X.W.; Chen, C.H.; Yao, M.; Li, C.C.; Lin, C.T.; Tsai, C.H.; Chou, W.C.; Hou, H.A.; Huang, S.Y.; et al. Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world’s largest retrospective cohort study. Br. J. Haematol. 2019, 186, 72–85. [Google Scholar] [CrossRef] [PubMed]
- Crooks, G.M.; Weinberg, K.; Mackall, C. Immune reconstitution: From stem cells to lymphocytes. Biol. Blood Marrow Transplant. 2006, 12, 42–46. [Google Scholar] [CrossRef] [PubMed]
- Azzi, J.R.; Sayegh, M.H.; Mallat, S.G. Calcineurin inhibitors: 40 years later, can’t live without. J. Immunol. 2013, 191, 5785–5791. [Google Scholar] [CrossRef] [PubMed]
- Löwenberg, M.; Verhaar, A.P.; van den Brink, G.R.; Hommes, D.W. Glucocorticoid signaling: A nongenomic mechanism for T-cell immunosuppression. Trends Mol. Med. 2007, 13, 158–163. [Google Scholar] [CrossRef]
- Tur-Kaspa, R.; Burk, R.D.; Shaul, Y.; Shafritz, D.A. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc. Natl. Acad. Sci. USA 1986, 83, 1627–1631. [Google Scholar] [CrossRef]
- Liang, R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009, 113, 3147–3153. [Google Scholar] [CrossRef]
- Mikulska, M.; Lanini, S.; Gudiol, C.; Drgona, L.; Ippolito, G.; Fernández-Ruiz, M.; Salzberger, B. ESCMID Study Group for Infections in Compromised Hosts (Esgich) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin. Microbiol. Infect. 2018, 24, S71–S82. [Google Scholar] [CrossRef]
- Seto, W.K.; Chan, T.S.; Hwang, Y.Y.; Wong, D.K.; Fung, J.; Liu, K.S.; Gill, H.; Lam, Y.F.; Lau, E.H.Y.; Cheung, K.S.; et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology 2017, 65, 1451–1461. [Google Scholar] [CrossRef]
- Kitano, K.; Kobayashi, H.; Hanamura, M.; Furuta, K.; Ueno, M.; Rokuhara, A.; Tanaka, E.; Umemura, T.; Kiyosawa, K. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur. J. Haematol. 2006, 77, 255–258. [Google Scholar] [CrossRef]
- Hui, C.-K.; Lie, A.; Au, W.-Y.; Leung, Y.-H.; Ma, S.-Y.; Cheung, W.W.W.; Zhang, H.-Y.; Chim, C.-S.; Kwong, Y.-L.; Liang, R.; et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005, 106, 464–469. [Google Scholar] [CrossRef]
- Onozawa, M.; Hashino, S.; Izumiyama, K.; Kahata, K.; Chuma, M.; Mori, A.; Kondo, T.; Toyoshima, N.; Ota, S.; Kobayashi, S.; et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005, 79, 616–619. [Google Scholar] [CrossRef]
- Varma, A.; Biritxinaga, L.; Saliba, R.M.; Stich, M.; Jauch, S.F.; Afrough, A.; Honhar, M.; Popat, U.R.; Shafi, M.A.; Shah, N.; et al. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol. Blood Marrow Transplant. 2017, 23, 581–587. [Google Scholar] [CrossRef] [Green Version]
- Bae, S.K.; Gushima, T.; Saito, N.; Yamanaka, I.; Matsuo, Y.; Yoshida, S.; Kawano, I.; Henzan, H.; Shimoda, S.; Eto, T.; et al. HBV reactivation after hematopoietic stem cell transplantation and rituximab-containing chemotherapy: A 12-year experience at a single center. Bone Marrow Transplant. 2019, 54, 629–631. [Google Scholar] [CrossRef] [PubMed]
- Hwang, J.P.; Barbo, A.G.; Perrillo, R.P. Hepatitis B reactivation during cancer chemotherapy: An international survey of the membership of the American Association for the Study of Liver Diseases. J. Viral Hepat. 2015, 22, 346–352. [Google Scholar] [CrossRef] [PubMed]
- Salpini, R.; Battisti, A.; Colagrossi, L.; Di Carlo, D.; Fabeni, L.; Piermatteo, L.; Cerva, C.; Lichtner, M.; Mastroianni, C.; Marignani, M.; et al. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. J. Viral Hepat. 2019, 26, 846–855. [Google Scholar] [CrossRef]
- Locasciulli, A.; Alberti, A.; Bandini, G.; Polchi, P.; Arcese, W.; Alessandrino, P.; Bosi, A.; Testa, M.; Bacigalupo, A. Allogeneic bone marrow transplantation from HBsAg+ donors: A multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 1995, 86, 3236–3240. [Google Scholar] [CrossRef]
- Lau, G.; He, M.; Fong, D.Y.T.; Bartholomeusz, A.; Au, W.; Lie, A.K.W.; Locarnini, S.; Liang, R. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002, 36, 702–709. [Google Scholar] [CrossRef]
- Yoo, J.J.; Cho, E.J.; Cho, Y.Y.; Lee, M.; Lee, D.H.; Cho, Y.; Lee, J.H.; Yu, S.J.; Yoon, S.S.; Yoon, J.H.; et al. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation. Liver Int. 2015, 35, 2530–2536. [Google Scholar] [CrossRef]
- Yeo, W.; Chan, P.K.; Zhong, S.; Ho, W.M.; Steinberg, J.L.; Tam, J.S.; Hui, P.; Leung, N.W.; Zee, B.; Johnson, P.J. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J. Med. Virol. 2000, 62, 299–307. [Google Scholar] [CrossRef]
- Jun, C.H.; Kim, B.S.; Oak, C.Y.; Lee, D.H.; Cho, E.; Cho, S.B.; Choi, S.K.; Park, C.H.; Joo, Y.E.; Lee, J.J.; et al. HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea. Hepatol. Int. 2017, 11, 87–95. [Google Scholar] [CrossRef]
- Simonetti, J.; Bulkow, L.; McMahon, B.J.; Homan, C.; Snowball, M.; Negus, S.; Williams, J.; Livingston, S.E. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010, 51, 1531–1537. [Google Scholar] [CrossRef] [PubMed]
- Chen, C.-Y.; Tien, F.-M.; Cheng, A.; Huang, S.-Y.; Chou, W.-C.; Yao, M.; Tang, J.-L.; Tien, H.-F.; Sheng, W.-H. Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. BMC Gastroenterol. 2018, 18, 6. [Google Scholar] [CrossRef] [PubMed]
- Paul, S.; Dickstein, A.; Saxena, A.; Terrin, N.; Viveiros, K.; Balk, E.M.; Wong, J.B. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis. Hepatology 2017, 66, 379–388. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, H.-C.; Tsou, H.-H.; Pei, S.-N.; Chang, C.-S.; Chen, J.-H.; Yao, M.; Lin, S.-J.; Lin, J.; Yuan, Q.; Xia, N.; et al. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J. Hepatol. 2018, 69, 286–292. [Google Scholar] [CrossRef]
- Lin, C.L.; Kao, J.H. Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. Best Pract. Res. Clin. Gastroenterol. 2017, 31, 249–255. [Google Scholar] [CrossRef]
- Socié, G.; Ritz, J. Current issues in chronic graft-versus-host disease. Blood 2014, 124, 374–384. [Google Scholar] [CrossRef] [Green Version]
- Gentile, G.; Antonelli, G. Interplay between β herpesviruses and fungal infections in transplant patients: From the bench to the bedside. Future Virol. 2015, 10, 399–414. [Google Scholar] [CrossRef]
- Marchesi, F.; Giannotti, F.; Avvisati, G.; Petti, M.C.; Pimpinelli, F.; Paba, P.; Dessanti, M.L.; Cerretti, R.; Tirindelli, M.C.; Picardi, A.; et al. The potential role of pre-transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network. Am. J. Hematol. 2012, 87, 213–217. [Google Scholar] [CrossRef]
- Liu, Y.C.; Lu, P.L.; Hsiao, H.H.; Chang, C.S.; Liu, T.C.; Yang, W.C.; Lin, S.F. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: Experience in a center with a high seroprevalence of both CMV and hepatitis B virus. Ann. Hematol. 2012, 91, 587–595. [Google Scholar] [CrossRef]
- Chen, Y.; Xu, L.-P.; Liu, K.-Y.; Chen, H.; Chen, Y.-H.; Zhang, X.-H.; Wang, Y.; Wang, F.-R.; Han, W.; Wang, J.-Z.; et al. Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. J. Clin. Virol. 2016, 75, 10–15. [Google Scholar] [CrossRef]
- Schuch, A.; Zecher, B.F.; Müller, P.A.; Correia, M.P.; Daul, F.; Rennert, C.; Tauber, C.; Schlitt, K.; Boettler, T.; Neumann-Haefelin, C.; et al. NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection. J. Hepatol. 2019, 70, 351–360. [Google Scholar] [CrossRef] [PubMed]
- Gill, U.S.; Golden-Mason, L. HCMV jogs the ‘memory’ of NK cells in HBV. J. Hepatol. 2019, 70, 343–345. [Google Scholar] [CrossRef] [PubMed]
- Torelli, G.F.; Lucarelli, B.; Iori, A.P.; De Propris, M.S.; Capobianchi, A.; Barberi, W.; Valle, V.; Iannella, E.; Natalino, F.; Mercanti, C.; et al. The immune reconstitution after an allogeneic stem cell transplant correlates with the risk of graft-versus-host disease and cytomegalovirus infection. Leuk. Res. 2011, 35, 1124–1126. [Google Scholar] [CrossRef] [PubMed]
- European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017, 67, 370–398. [Google Scholar] [CrossRef] [Green Version]
- Hsiao, L.-T.; Chiou, T.-J.; Liu, J.-H.; Chu, C.-J.; Lin, Y.-C.; Chao, T.-C.; Wang, W.-S.; Yen, C.-C.; Yang, M.-H.; Tzeng, C.-H.; et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant. 2006, 12, 84–94. [Google Scholar] [CrossRef]
- Teh, B.W.; Slavin, M.A.; Szer, J.; Sasadeusz, J.J. Hepatitis B serological changes following allogeneic bone marrow transplantation. Transpl. Infect. Dis. 2013, 15, 98–103. [Google Scholar] [CrossRef]
- Shang, J.; Wang, H.; Sun, J.; Fan, Z.; Huang, F.; Zhang, Y.; Jiang, Q.; Dai, M.; Xu, N.; Lin, R.; et al. A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: A single-institutional experience. Bone Marrow Transplant. 2016, 51, 581–586. [Google Scholar] [CrossRef]
- Siyahian, A.; Malik, S.U.; Mushtaq, A.; Howe, C.L.; Majeed, A.; Zangeneh, T.; Iftikhar, S.; Habib, S.; Zahid, U.; Riaz, I.B.; et al. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. Biol. Blood Marrow Transplant. 2018, 24, 1483–1489. [Google Scholar] [CrossRef] [Green Version]
- Hilgendorf, I.; Loebermann, M.; Borchert, K.; Junghanss, C.; Freund, M.; Schmitt, M. Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD. Bone Marrow Transplant. 2011, 46, 1274–1275. [Google Scholar] [CrossRef]
- Di Bisceglie, A.M.; Lok, A.S.; Martin, P.; Terrault, N.; Perrillo, R.P.; Hoofnagle, J.H. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg? Hepatology 2015, 61, 703–711. [Google Scholar] [CrossRef]
- Arora, A.; Anand, A.C.; Kumar, A.; Singh, S.P.; Aggarwal, R.; Dhiman, R.K.; Aggarwal, S.; Alam, S.; Bhaumik, P.; Dixit, V.K.; et al. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J. Clin. Exp. Hepatol. 2018, 8, 403–431. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Loomba, R.; Liang, T.J. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology 2017, 152, 1297–1309. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, S.; Kim, K.; Kim, D.H.; Jang, J.H.; Kim, S.J.; Kim, W.S.; Jung, C.W.; Koh, K.C. Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus. Biol. Blood Marrow Transplant. 2011, 17, 1630–1637. [Google Scholar] [CrossRef] [PubMed]
- Knoll, A.; Boehm, S.; Hahn, J.; Holler, E.; Jilg, W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: High risk of viral reactivation even in a recipient with a vaccinated donor. J. Viral Hepat. 2007, 14, 478–483. [Google Scholar] [CrossRef]
- Zappulo, E.; Nicolini, L.A.; Di Grazia, C.; Dominietto, A.; Lamparelli, T.; Gualandi, F.; Caligiuri, P.; Bruzzone, B.; Angelucci, E.; Viscoli, C.; et al. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab. Infection 2019, 47, 59–65. [Google Scholar] [CrossRef]
- Cerva, C.; Colagrossi, L.; Maffongelli, G.; Salpini, R.; di Carlo, D.; Malagnino, V.; Battisti, A.; Ricciardi, A.; Pollicita, M.; Bianchi, A.; et al. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxisin haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients withan anti-HBc-positive donor. Clin. Microbiol. Infect. 2016, 22, 946. [Google Scholar] [CrossRef]
- Gupta, A.; Punatar, S.; Gawande, J.; Bagal, B.; Mathew, L.; Bhat, V.; Kannan, S.; Khattry, N. Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation. Hematol. Oncol. 2016, 34, 140–146. [Google Scholar] [CrossRef]
- Reddy, K.R.; Beavers, K.L.; Hammond, S.P.; Lim, J.K.; Falck-Ytter, Y.T.; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015, 148, 215–219. [Google Scholar] [CrossRef]
- Hwang, J.P.; Somerfield, M.R.; Alston-Johnson, D.E.; Cryer, D.R.; Feld, J.J.; Kramer, B.S.; Sabichi, A.L.; Wong, S.L.; Artz, A.S. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J. Clin. Oncol. 2015, 33, 2212–2220. [Google Scholar] [CrossRef]
- Lau, G.K.K.; Lie, A.K.W.; Kwong, Y.L.; Lee, C.K.; Hou, J.; Lau, Y.L.; Lim, W.L.; Liang, R. A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 2000, 96, 452–458. [Google Scholar] [CrossRef]
- Hui, C.-K.; Lie, A.; Au, W.-Y.; Ma, S.-Y.; Leung, Y.-H.; Zhang, H.-Y.; Sun, J.; Cheung, W.W.; Chim, C.-S.; Kwong, Y.-L.; et al. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am. J. Transplant. 2005, 5, 1437–1445. [Google Scholar] [CrossRef] [PubMed]
- Giaccone, L.; Festuccia, M.; Marengo, A.; Resta, I.; Sorasio, R.; Pittaluga, F.; Fiore, F.; Boccadoro, M.; Rizzetto, M.; Bruno, B.; et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 2010, 16, 809–817. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Liu, J.; Huang, B.; Zheng, D.; Chen, M.; Zhou, Z.; Xu, D.; Zou, W. Hepatitis B virus infection status is an independent risk factor for multiple myeloma patients after autologous hematopoietic stem cell transplantation. Tumor Biol. 2013, 34, 1723–1728. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Huang, B.; Li, Y.; Zheng, D.; Zhou, Z.; Liu, J. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leuk. Lymphoma 2015, 56, 1710–1717. [Google Scholar] [CrossRef]
- Tsukune, Y.; Sasaki, M.; Odajima, T.; Sunami, K.; Takei, T.; Moriuchi, Y.; Iino, M.; Isoda, A.; Nakaya, A.; Muta, T.; et al. Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: A nationwide retrospective study in Japan. Blood Cancer J. 2017, 7, 631. [Google Scholar] [CrossRef]
- Cordonnier, C.; Einarsdottir, S.; Cesaro, S.; Di Blasi, R.; Mikulska, M.; Rieger, C.; de Lavallade, H.; Gallo, G.; Lehrnbecher, T.; Engelhard, D.; et al. Vaccination of haemopoietic stem cell transplant recipients: Guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect. Dis. 2019, 19, e200–e212. [Google Scholar] [CrossRef]
- Jaffe, D.; Papadopoulos, E.B.; Young, J.W.; O’Reilly, R.J.; Prockop, S.; Kernan, N.A.; Jakubowski, A.; Boulad, F.; Perales, M.-A.; Castro-Malaspina, H.; et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 2006, 108, 2470–2475. [Google Scholar] [CrossRef]
- Kaloyannidis, P.; Batsis, I.; Yannaki, E.; Adamidou, D.; Bartzoudis, D.; Papathanasiou, M.; Mallouri, D.; Sakellari, I.; Fassas, A.; Anagnostopoulos, A. Allografted recipients immunized against hepatitis B virus are at high risk of gradual surface antibody (HbsAb) disappearance post transplant, regardless of adoptive immunity transfer. Biol. Blood Marrow Transplant. 2007, 13, 1049–1056. [Google Scholar] [CrossRef]
- Takahata, M.; Hashino, S.; Onozawa, M.; Shigematsu, A.; Sugita, J.; Fujimoto, K.; Endo, T.; Kondo, T.; Tanaka, J.; Imamura, M.; et al. Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: Long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl. Infect. Dis. 2014, 16, 797–801. [Google Scholar] [CrossRef]
- Mallet, V.; van Bömmel, F.; Doerig, C.; Pischke, S.; Hermine, O.; Locasciulli, A.; Cordonnier, C.; Berg, T.; Moradpour, D.; Wedemeyer, H.; et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: Recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect. Dis. 2016, 16, 606–617. [Google Scholar] [CrossRef]
- Lindemann, M.; Koldehoff, M.; Fiedler, M.; Schumann, A.; Ottinger, H.D.; Heinemann, F.M.; Roggendorf, M.; Horn, P.A.; Beelen, D.W. Control of hepatitis B virus infection in hematopoietic stem cell recipients after receiving grafts from vaccinated donors. Bone Marrow Transplant. 2016, 51, 428–431. [Google Scholar] [CrossRef] [PubMed]
- Le, Q.; Shenoy, A.; Koklanaris, E.; Childs, R.; Barrett, A.J.; Savani, B.N. Lamivudine prophylaxis and hepatitis B vaccination for prevention of hepatitis B virus reverse seroconversion in long-term survivors after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 2009, 15, 886–887. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gentile, G.; Antonelli, G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses 2019, 11, 1049. https://doi.org/10.3390/v11111049
Gentile G, Antonelli G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019; 11(11):1049. https://doi.org/10.3390/v11111049
Chicago/Turabian StyleGentile, Giuseppe, and Guido Antonelli. 2019. "HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review" Viruses 11, no. 11: 1049. https://doi.org/10.3390/v11111049